Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain imaging examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    225 result(s) found for: Brain imaging examination. Displaying page 7 of 12.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2015-004214-14 Sponsor Protocol Number: P311-201 Start Date*: 2016-10-13
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts f...
    Medical condition: Advanced Solid Tumors/Relapsed/Recurrent Glioblastoma Multiforme (GBM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005177-29 Sponsor Protocol Number: EORTC 26052-22053 Start Date*: 2006-11-10
    Sponsor Name:EORTC
    Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma
    Medical condition: Patients with Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2020-005549-17 Sponsor Protocol Number: FAPI-MN-2020 Start Date*: 2021-04-21
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: Role of [68Ga]Ga-FAPI PET/CT in oncological patients with doubtful or inconclusive findings at [18F]F-FDG PET/CT
    Medical condition: oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT ima...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001876-32 Sponsor Protocol Number: SLN360-002 Start Date*: 2023-04-14
    Sponsor Name:Silence Therapeutics plc
    Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at...
    Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10022891 - Investigations 10054009 Lipoprotein (a) increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) SK (Completed) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-001291-56 Sponsor Protocol Number: A8241021 Start Date*: 2014-10-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE
    Medical condition: HUNTINGTON’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    19.0 10010331 - Congenital, familial and genetic disorders 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005724-10 Sponsor Protocol Number: SPIHF-201 Start Date*: 2016-06-07
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart...
    Medical condition: Stable Heart Failure with Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001800-31 Sponsor Protocol Number: GN39763 Start Date*: 2018-04-06
    Sponsor Name:Genentech Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE
    Medical condition: Alzheimer's Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DK (Completed) FI (Prematurely Ended) DE (Prematurely Ended) PL (Completed) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001411-39 Sponsor Protocol Number: ABT-002 Start Date*: 2018-09-04
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
    Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005280-27 Sponsor Protocol Number: AFF006A Start Date*: 2013-06-11
    Sponsor Name:AFFiRiS AG
    Full Title: A randomized, controlled, parallel group, double-blind, multi-centre, phase IIb study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations of patients who participated in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) SK (Completed) HR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001326-15 Sponsor Protocol Number: RXDX-101-01 Start Date*: 2014-10-15
    Sponsor Name:Ignyta Inc.
    Full Title: A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alter...
    Medical condition: Locally advanced or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10065252 Solid tumor LLT
    17.0 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-000418-75 Sponsor Protocol Number: TV5600-CNS-20007 Start Date*: 2014-11-18
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients...
    Medical condition: Huntington's Disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003928-23 Sponsor Protocol Number: E2609-G000-301 Start Date*: 2017-08-11
    Sponsor Name:Eisai Ltd.
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease
    Medical condition: Early Alzheimer Disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-001739-38 Sponsor Protocol Number: TAK-831-2001 Start Date*: 2017-09-19
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-000552-33 Sponsor Protocol Number: LUMC_2012 Start Date*: 2012-11-27
    Sponsor Name:Leiden University Medical Center
    Full Title: Adoptive T cell therapy plus vaccination in metastatic melanoma patients
    Medical condition: Metastasized melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002471-25 Sponsor Protocol Number: BN40697(ISIS443139-CS2) Start Date*: 2018-10-18
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVES...
    Medical condition: Early Manifest Huntington's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003556-31 Sponsor Protocol Number: SHP-607-201 Start Date*: 2015-02-10
    Sponsor Name:Premacure AB, A Member of the Shire Group of Companies
    Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000954-86 Sponsor Protocol Number: 107CS-5 Start Date*: 2020-08-17
    Sponsor Name:Daehwa Pharmaceutical Co., Ltd.
    Full Title: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients wit...
    Medical condition: Recurrent or metastatic HER2 negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001824-43 Sponsor Protocol Number: DS1040-A-U103 Start Date*: 2016-02-04
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, p...
    Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) CZ (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000845-11 Sponsor Protocol Number: TIRCON2012V1 Start Date*: 2012-07-16
    Sponsor Name:ApoPharma Inc.
    Full Title: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)
    Medical condition: Pantothenate kinase-associated neurodegeneration (PKAN)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005755-20 Sponsor Protocol Number: ALZ-801-AD301 Start Date*: 2021-06-21
    Sponsor Name:Alzheon, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype
    Medical condition: Early Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 02 14:17:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA